Which Is the Better Small-Cap Value ETF, iShares' ISCV or Vanguard's VBR?

The iShares Morningstar Small-Cap Value ETF returned 27.10% over the last 12 months versus 24.80% for Vanguard Small-Cap Value ETF, while Vanguard remains far larger at $64.9 billion in AUM compared with $656.6 million for iShares. Both funds are low-cost, with expense ratios of 0.06% and 0.05%, and provide exposure to more than 800 small-cap value stocks. The article frames the choice as a tradeoff between ISCV’s stronger recent performance and diversification versus VBR’s superior liquidity, lower drawdown, and larger scale.

Analysis

The market is effectively telling us this is not a fund-level story so much as a factor-exposure story: small-cap value is being rewarded, but the winners inside the basket are likely the most operationally levered, not the most statistically cheap. The higher weights in financials, industrials, and cyclicals mean the better-performing ETF is probably benefiting from a more aggressive exposure to domestic activity and rate-sensitive balance sheets, while the larger fund’s scale is insulating it from micro-cap noise and trading frictions. In other words, the “better” fund over the last year may simply have more of the right beta at the right time, rather than superior security selection.

The second-order issue is that low AUM can become a hidden tax even when the headline expense ratio is close. A smaller vehicle can underperform its index during stress because market impact, wider spreads, and forced rebalancing costs show up exactly when small caps are most fragile; that risk compounds over months, not days. Conversely, the huge, liquid fund is more likely to remain the default institutional sleeve, so any retail-driven performance chase into the smaller ETF could actually worsen execution quality and erase part of the apparent return edge.

The contrarian read is that the “more diversified” fund may be marginally less diversified where it matters: at the factor level. If financials and industrials roll over, the broader holding count won’t protect against correlated downside because small-cap value behaves like a rates-and-growth proxy in disguise. The key reversal catalyst is a macro regime shift: if real rates fall or recession probability rises, the recent leadership can unwind quickly as cyclicals de-rate and dividend yield stops being enough to compensate for earnings risk.

Key Decisions for Investors

• Prefer VBR over ISCV for core exposure over the next 6-12 months: the liquidity advantage and tighter trading costs matter more than a few bps of fee difference when volatility spikes; use ISCV only for small tactical allocations where spread cost is immaterial.
• Pair trade idea: long VBR / short IWM for 3-6 months if you want pure small-cap value factor exposure with less balance-sheet risk; thesis is that value-rich cyclicals hold up better than the broad small-cap complex if growth cools but recession is avoided.
• For a tactical trade, buy 1-2 month call spreads on VBR into any 2-3% pullback in small caps; risk/reward is attractive if lower rates and improving domestic PMIs continue to support financials/industrials.
• Avoid chasing ISCV after a strong 12-month run unless you can work the order slowly: the smaller AUM makes implementation risk meaningful, so use limit orders only and assume 10-20 bps of hidden slippage in stressed sessions.
• If rates back up materially or cyclicals start underperforming the market for 2-3 weeks, cut small-cap value exposure by 25-50%: that is the cleanest early warning that the factor tailwind is fading.